Jul 30, 2018 · Some therapeutic antibody drugs have been designed to target cells that have a particular type of CD marker (e.g, rituximab to CD20 for lymphomas and leukemia treatment; alemtuzumab to CD52 for chronic lymphocytic leukemia and T-cell lymphoma treatment).

Sep 20, 2021 · FMC7 detects a conformational epitope on the CD20 molecule with probable cholesterol dependency (Cytometry 2001;46:98, Leukemia 2003;17:1384) Clinical features Rituximab is a chimeric murine / human anti-CD20 antibody used to treat B cell lymphomas; treatment may cause selection of CD20 negative (but CD79a positive) tumor subclones ( Am J …

If the lymphocytic proliferation stains positive with CD20, a B-cell immunophenotypic work-up is warranted and includes CD5, CD10, CD43, CD79a, Bcl-2, and Bcl-6 . CD5, CD20, and CD79a are pan B-cell markers. CD10 is a characteristic marker …

The marker CD20 is positive in most of the B-cell lymphomas except mature B-cells/plasma cell neoplasms such as multiple myeloma/solitary plasmacytoma and plasmablastic lymphoma. CD20 is negative in all the T-cell lymphomas.

Jul 7, 2023 · CD markers are small molecules that serve as ID tags on the outside of different cell types. They are used in the diagnosis and treatment of cancer.

Immunohistochemical examinations revealed positivity for PAS, CK7 and CDX-2, focal positivity for CK20 and negativity for PSA and PSAP. The diagnosis of a prostatic secondary SRCC was possible given the positivity to CK7, CDX-2, focal positivity to CK20 and negativity to PSA.

CD molecules can act in numerous ways, often acting as receptors or ligands (the molecule that activates a receptor) important to the cell. A signal cascade is usually initiated, altering the behavior of the cell (see cell signaling). Some CD proteins do not play a role in cell signaling, but have other functions, such as cell adhesion.

Mar 26, 2025 · CD20 is a CD marker—a molecule on the cell surface that can be used to identify and type a particular cell in the body. CD20 is found on the surface of B cells (a type of immune system cell). But let's back up and make this easier to understand.

Jul 1, 2013 · Here is a list of commonly-used markers, sent in by a very nice reader who knows a lot about this stuff. Some markers are used in more than one instance (for example, CD15 is present on both Reed-Sternberg cells and neutrophils). Note that they are listed, for the most part, in numerical order.

CD20 is the target of the mAbs rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.